PPARA and metabolic dysfunction-associated steatohepatitis: Interestingly, the pan PPAR agonist lanifibranor showed encouraging data with NASH resolution without worsening of fibrosis in addition to a beneficial lipid profile with increased HDL cholesterol and reduced triglycerides [214].